Certara’s Secondary Intelligence Software Predicts Likelihood of New Drug Candidates Causing Safety Concerns
Established in 1963, the R&D 100 Awards is the only S&T (science and technology) awards competition that recognizes new commercial products, technologies, and materials for their technological significance that are available for sale or license. The R&D 100 Awards, celebrating the program's 60th Anniversary this year, has long been a benchmark of excellence for industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology. This 2022 R&D 100 winner is listed below, along with its respective category.
Category: Software/Services
Developers: Certara
United States
Product Description:Certara’s Secondary Intelligence software assembles, curates, and visualizes secondary pharmacology analyses. It assesses, and quantitatively rates, the likelihood of new drug candidates producing off-target activity, causing safety concerns. Early identification of this potential activity helps to reduce the incidence of adverse drug reactions, which could impede candidates’ clinical progress.
Developers: Certara
United States
Product Description:Certara’s Secondary Intelligence software assembles, curates, and visualizes secondary pharmacology analyses. It assesses, and quantitatively rates, the likelihood of new drug candidates producing off-target activity, causing safety concerns. Early identification of this potential activity helps to reduce the incidence of adverse drug reactions, which could impede candidates’ clinical progress.
Secondary Intelligence Screenshot